Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 2Neuroectodermal Tumors, Primitive 1Neoplasms 1Glioblastoma 1Brain Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 3Fluorodeoxyglucose F18 2FAPI-46 2fluorodopa F 18 1entrectinib 1dactolisib 1alectinib 1Specimen Handling 1Respiratory Therapy 1Quality of Life 1Positron-Emission Tomography 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Immunotherapy 1Furosemide 1Everolimus 1Drug Therapy 1Biological Therapy 14-chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Brain Neoplasms × dactolisib × NET × Clear all
NCT01508104 2017-08-23

Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors

University of Cincinnati

Phase 1 Terminated
19 enrolled
CNSEndocrineNET

Brain Neoplasms, Glioblastoma, Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡